[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][NH:11][C:10](=[O:14])[CH2:9]1)=[O:7])([CH3:4])(C)C.[C:15]([O:19][C:20]([N:22]1[CH2:27][CH2:26][CH:25]([CH2:28][CH2:29][CH2:30]Br)[CH2:24][CH2:23]1)=[O:21])([CH3:18])([CH3:17])[CH3:16].BrC[C:34]1[CH:43]=[C:42]2C(C(Cl)=NC=N2)=[CH:36][CH:35]=1>>[CH2:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][N:11]([CH2:30][CH2:29][CH2:28][CH:25]2[CH2:26][CH2:27][N:22]([C:20]([O:19][C:15]([CH3:18])([CH3:17])[CH3:16])=[O:21])[CH2:23][CH2:24]2)[C:10](=[O:14])[CH2:9]1)=[O:7])[C:4]1[CH:42]=[CH:43][CH:34]=[CH:35][CH:36]=1The title compound is prepared as described in EXAMPLE 72, Part A, substituting 3-oxopiperazine-1-carboxylic acid benzyl ester for 3-oxopiperazine-1-carboxylic acid tert-butyl ester and 4-(3-bromopropyl)-piperidine-1-carboxylic acid tert-butyl ester for 7-bromomethyl-4-chloroquinazoline. The title compound is obtained as a white foam. 1H NMR (CDCl3, 300 MHz) δ7.38 (m, 5H), 5.12 (s, 2H), 4.18 (m, 4H), 3.73 (m, 2H), 3.33 (m, 4H), 2.66 (m, 2H), 1.58 (m, 6H), 1.42 (s, 9H), 1.38 (m, 3H).